Further, while ACTG1 gain was found to be associated with increased PRC2 activity, EZH2, a core member of the PRC2 complex and an oncogenic target in several cancers [23,24,25,26] was not altered in the same patient samples (Figure 4B). This evidence concerns the gene EZH2 and cancer.